Nkarta, Inc. (NASDAQ:NKTX) Receives $13.50 Average Target Price from Brokerages

Shares of Nkarta, Inc. (NASDAQ:NKTX) have received a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $13.50.

Several brokerages have recently issued reports on NKTX. Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a report on Friday, October 31st. Stifel Nicolaus lowered their target price on Nkarta from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Nkarta in a research report on Wednesday, August 13th.

Nkarta Trading Down 0.5%

NKTX stock opened at $1.96 on Friday. The firm’s 50-day moving average is $2.14 and its two-hundred day moving average is $2.02. The company has a market capitalization of $139.22 million, a price-to-earnings ratio of -1.32 and a beta of 0.86. Nkarta has a 52 week low of $1.31 and a 52 week high of $3.81.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. On average, equities research analysts predict that Nkarta will post -1.7 earnings per share for the current year.

Institutional Trading of Nkarta

A number of hedge funds and other institutional investors have recently made changes to their positions in NKTX. American Century Companies Inc. boosted its holdings in Nkarta by 6.5% during the first quarter. American Century Companies Inc. now owns 96,838 shares of the company’s stock worth $178,000 after buying an additional 5,886 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Nkarta by 35.0% during the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock valued at $49,000 after acquiring an additional 6,141 shares during the last quarter. CWM LLC lifted its position in shares of Nkarta by 23.4% during the 2nd quarter. CWM LLC now owns 34,758 shares of the company’s stock valued at $58,000 after acquiring an additional 6,601 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Nkarta by 4.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 231,081 shares of the company’s stock worth $384,000 after acquiring an additional 8,968 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Nkarta by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock worth $2,006,000 after acquiring an additional 10,065 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.